226. 間質性膀胱炎(ハンナ型) Interstitial cystitis with Hunners ulcer Clinical trials / Disease details


臨床試験数 : 145 薬物数 : 156 - (DrugBank : 51) / 標的遺伝子数 : 64 - 標的パスウェイ数 : 146

  
7 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2009-014597-17-SE
(EUCTR)
03/05/201028/10/2009A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS)A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) Chronic pain including the pain of interstitial cystitis/painful bladder syndrome.
MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis
Product Name: Tanezumab
Product Code: PF-04383119
INN or Proposed INN: Tanezumab
Other descriptive name: RN624, RI624
Product Name: Tanezumab
Product Code: PF-04383119
INN or Proposed INN: Tanezumab
Other descriptive name: RN624, RI624
Product Name: Tanezumab
Product Code: PF-04383119
INN or Proposed INN: Tanezumab
Other descriptive name: RN624, RI624
Pfizer Inc., 235 East 42nd Street, New York, NY 10017NULLNot RecruitingFemale: yes
Male: yes
300Phase 2Finland;Spain;Belgium;Germany;Sweden
2EUCTR2009-014597-17-FI
(EUCTR)
24/03/201004/12/2009A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS)A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) Chronic pain including the pain of interstitial cystitis/painful bladder syndrome.
MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis
Product Name: Tanezumab
Product Code: PF-04383119
INN or Proposed INN: Tanezumab
Other descriptive name: RN624, RI624
Product Name: Tanezumab
Product Code: PF-04383119
INN or Proposed INN: Tanezumab
Other descriptive name: RN624, RI624
Product Name: Tanezumab
Product Code: PF-04383119
INN or Proposed INN: Tanezumab
Other descriptive name: RN624, RI624
Pfizer Inc., 235 East 42nd Street, New York, NY 10017NULLNot RecruitingFemale: yes
Male: yes
300Phase 2Slovakia;Finland;Spain;Belgium;Germany;Sweden
3EUCTR2009-014597-17-DE
(EUCTR)
19/03/201003/12/2009A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS)A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) Chronic pain including the pain of interstitial cystitis/painful bladder syndrome.
MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis
Product Name: Tanezumab
Product Code: PF-04383119
INN or Proposed INN: Tanezumab
Other descriptive name: RN624, RI624
Product Name: Tanezumab
Product Code: PF-04383119
INN or Proposed INN: Tanezumab
Other descriptive name: RN624, RI624
Product Name: Tanezumab
Product Code: PF-04383119
INN or Proposed INN: Tanezumab
Other descriptive name: RN624, RI624
Pfizer Inc., 235 East 42nd Street, New York, NY 10017NULLNot RecruitingFemale: yes
Male: yes
300Phase 2Finland;Germany;Belgium;Spain;Sweden
4EUCTR2009-014597-17-ES
(EUCTR)
08/02/201012/11/2009A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS)ESTUDIO EN FASE 2B, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO DE DETERMINACIÓN DE DOSIS PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE TANEZUMAB EN EL TRATAMIENTO DEL DOLOR MODERADO A INTENSO ASOCIADO A CISTITIS INTERSTICIAL/SÍNDROME DE LA VEJIGA DOLOROSA (CI/SVD)A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS)ESTUDIO EN FASE 2B, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO DE DETERMINACIÓN DE DOSIS PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE TANEZUMAB EN EL TRATAMIENTO DEL DOLOR MODERADO A INTENSO ASOCIADO A CISTITIS INTERSTICIAL/SÍNDROME DE LA VEJIGA DOLOROSA (CI/SVD) Tratamiento del dolor crónico incluyendo el dolor debido a cististis intersticial/síndrome de la vejiga dolorosa
MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis
Product Name: Tanezumab
Product Code: PF-04383119
INN or Proposed INN: Tanezumab
Other descriptive name: RN624, RI624
Product Name: Tanezumab
Product Code: PF-04383119
INN or Proposed INN: Tanezumab
Other descriptive name: RN624, RI624
Product Name: Tanezumab
Product Code: PF-04383119
INN or Proposed INN: Tanezumab
Other descriptive name: RN624, RI624
Pfizer, S.A.NULLNot RecruitingFemale: yes
Male: yes
300Phase 2Finland;Belgium;Spain;Germany;Sweden
5EUCTR2009-014597-17-SK
(EUCTR)
03/02/201011/02/2010A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS)A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) Chronic pain including the pain of interstitial cystitis/painful bladder syndrome.
MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis
Product Name: Tanezumab
Product Code: PF-04383119
INN or Proposed INN: Tanezumab
Other descriptive name: RN624, RI624
Product Name: Tanezumab
Product Code: PF-04383119
INN or Proposed INN: Tanezumab
Other descriptive name: RN624, RI624
Product Name: Tanezumab
Product Code: PF-04383119
INN or Proposed INN: Tanezumab
Other descriptive name: RN624, RI624
Pfizer Inc., 235 East 42nd Street, New York, NY 10017NULLNot RecruitingFemale: yes
Male: yes
300Phase 2Slovakia;Finland;Spain;Belgium;Germany;Sweden
6EUCTR2009-014597-17-BE
(EUCTR)
24/12/200909/11/2009A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS)A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS) Chronic pain including the pain of interstitial cystitis/painful bladder syndrome.
MedDRA version: 12.0;Level: LLT;Classification code 10008927;Term: Chronic interstitial cystitis
Product Name: Tanezumab
Product Code: PF-04383119
INN or Proposed INN: Tanezumab
Other descriptive name: RN624, RI624
Product Name: Tanezumab
Product Code: PF-04383119
INN or Proposed INN: Tanezumab
Other descriptive name: RN624, RI624
Product Name: Tanezumab
Product Code: PF-04383119
INN or Proposed INN: Tanezumab
Other descriptive name: RN624, RI624
Pfizer Inc., 235 East 42nd Street, New York, NY 10017NULLNot RecruitingFemale: yes
Male: yes
300Phase 2Slovakia;Finland;Spain;Belgium;Germany;Sweden
7NCT00601484
(ClinicalTrials.gov)
March 200815/1/2008An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial CystitisA Phase 2, 16 Week, Multicenter, Randomized, Double Blind Placebo Controlled, Parallel Group Proof Of Concept Study Evaluating The Efficacy And Safety Of PF-04383119 For The Treatment Of Pain Associated With Interstitial CystitisCystitis, InterstitialDrug: PF-04383119;Drug: PlaceboPfizerNULLCompleted18 YearsN/ABoth65Phase 2United States